ORIGINAL RESEARCH article
Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1667473
This article is part of the Research TopicCommunity Series in Novel Biomarkers in Tumor Immunity and Immunotherapy: Volume IIIView all 3 articles
Application of a risk score model based on tyrosine-related genes in the prognosis and treatment of patients with lung adenocarcinoma
Provisionally accepted- 1The First Affiliated Hospital With Nanjing Medical University, Nanjing, China
- 2Xiaoxian People's Hospital, anhui, China
- 3Xuzhou Central Hospital, Xuzhou, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: Tyrosine is associated with alterations in the tricarboxylic acid cycle in lung cancer, and exploring tyrosine-related genes (TRGs) has the potential to contribute to the construction of new sensitive prognostic biomarkers for patients with lung adenocarcinoma (LUAD). Method: Lung cancer prognosis model was constructed by Lasso Cox regression, univariate and multivariate COX regression, GSEA, TIDE. Potential drugs were screened and drug sensitivities analyzed by the pRRophetic software package. And the role of MYO6 in lung cancer was confirmed by experiments in vitro. Results: We identified 7 TRG risk score models (ZFP3, MEAK7, MMUR1, GTF3C6, MYO6, MAPK1IP1L and VAX1) for the diagnosis and prognosis of patients with LUAD. ROC curves and the C-index suggested that the risk score had more reliable diagnostic significance and could more accurately predict the prognosis of LUAD patients. The nomogram model was constructed with risk scores, which can be used to predict an individual and visualize the correlation between the total score and the predicted outcome more intuitively. Additionally, it has an impact on immunotherapy efficacy, tumor mutation burden and drug sensitivity. In addition, high expression of myosin VI (MYO6) was related to tumor proliferation and metastasis in vitro. Conclusion: In conclusion, the risk scores constructed from seven TRGs have great potential for survival prognosis, immunotherapy response and drug sensitivity. MYO6 plays an oncogenic role in promoting proliferation and metastasis in patients with LUAD, which provides a new theoretical basis for the diagnosis and treatment of LUAD patients.
Keywords: LUAD, Tyrosine, immune, MYO6, Signature
Received: 16 Jul 2025; Accepted: 22 Oct 2025.
Copyright: © 2025 Wang, Yuebei, Liu and Fan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Xinyuan Fan, 17705219945@163.com
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.